Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11914560 | 0.87 | ADRB3 (0.78) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Hydrochloric Acid SCHEMBL28729981 | 0.86 | ADRB3 (0.76) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL28636391 | 0.84 | ADRB3 (0.72) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609245 | 0.82 | ADRB3 (0.73) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL904789 | 0.82 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL904788 | 0.82 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL805237 | 0.82 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993771 | 0.81 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1509286 | 0.81 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1405678 | 0.81 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
| EP-1703903-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING STRESS INCONTINENCE AND/OR MIXED INCONTINENCE | Boehringer Ingelheim International GmbH (DE) | 2006-09-27 | — | — | EP | disclosed |
| EP-1689382-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND AN AGENT INTERVENING IN THE PROSTAGLANDIN METABOLISM | Boehringer Ingelheim International GmbH (DE) | 2006-08-16 | — | — | EP | disclosed |
| EP-1682183-A2 | PHARMACEUTICAL COMPOSITION, CONTAINING A BETA-3-ADRENOCEPTOR AGONIST AND AN ALPHA ANTAGONIST AND/OR A 5-ALPHA-REDUCTASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1640000-A2 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | Boehringer Ingelheim International GmbH (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-20060004105-A1 | Pharmaceutical composition for treating stress incontinence and/or mixed incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20050261369-A1 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1572181-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND A SEROTONIN AND/OR NOREPINEPHRINE REUPTAKE INHIBITOR AND THE USE OF SAID COMPOSITION FOR TREATING BLADDER DYSFUNCTION | Boehringer Ingelheim International GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| WO-2005060955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND AN AGENT INTERVENING IN THE PROSTAGLANDIN METABOLISM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-07 | — | — | WO | disclosed |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005046666-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING STRESS INCONTINENCE AND/OR MIXED INCONTINENCE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| WO-2005042021-A2 | PHARMACEUTICAL COMPOSITION, CONTAINING A BETA-3-ADRENOCEPTOR AGONIST AND AN ALPHA ANTAGONIST AND/OR A 5-ALPHA-REDUCTASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004047830-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND A SEROTONIN AND/OR NOREPINEPHRINE REUPTAKE INHIBITOR AND THE USE OF SAID COMPOSITION FOR TREATING BLADDER DYSFUNCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB1 1/4885ADRB2 3/4885 |
| US-20050261369-A1 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20060004105-A1 | Pharmaceutical composition for treating stress incontinence and/or mixed incontinence | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.